Treatment tolerability in mHSPC and nmCRPC

Description

Discover these expert opinions on the management and treatment of patients prescribed NUBEQA in clinical practice. These two informative videos feature leading oncologists, Professor Alison Birtle and Dr. Amar Challapalli, who provide their valuable perspective on understanding patient goals in mHSPC and nmCRPC, the significance of patient selection and the importance of maintaining quality of life when selecting a treatment for your patients. 

Stay informed and enhance your clinical practice with these expert insights: 

NUBEQA Prescribing Information

ARASENS trial. Men with mHSPC. NUBEQA + ADT + docetaxel (n=651) vs. placebo + ADT + docetaxel (n=654). Primary endpoint was OS. The most frequently observed adverse reactions in patients with mHSPC receiving NUBEQA are hypertension, rash, blood bilirubin increased, ALT increased, AST increased (≥1/10). The most common serious adverse reactions in patients receiving darolutamide in combination with docetaxel were febrile neutropenia (6.1%), neutrophil count decreased (2.8%) and pneumonia (2.5%). 

NUBEQA Prescribing Information

ARAMIS trial. Men with high-risk nmCRPC. NUBEQA + ADT (n=955) vs. placebo + ADT (n=554). Primary endpoint was median metastasis free survival (MFS), secondary endpoint was overall survival (OS). Number of patients with events 148/955 (15.5%) vs. 106/554 (19.1%) with placebo + ADT. Final analysis for OS was conducted after 254 deaths. 

The most frequently observed adverse reactions in patients with nmCRPC receiving NUBEQA were fatigue/asthenic conditions, neutrophil count decreased, blood bilirubin increased and AST increased (≥1/10), and rash, pain in the extremity, musculoskeletal pain, fractures, ischaemic heart disease and heart failure (≥1/100).